Its prolonged half-life makes it a useful reference compound for studying sustained GLP-1 receptor engagement in preclinical models
Ameliorating effect of luteolin on memory impairment in an Alzheimers disease model
Zepbound, a dual GIP/GLP-1 agonist, enhances treatment results by targeting two hormonal pathways for superior weight loss efficacy
It is clear these medications have great clinical benefits, may provide for long-term positive financial ROI, and may provide less-tangible benefits (e.g., employee attraction / retention), but I have not yet seen any strong evidence demonstrating a positive financial ROI in the near-term
Saves time on manual computations and unit conversions (mg, mcg, IU)
Additionally, the real-world effectiveness (whether individuals will benefit as much as they do in clinical trials) is still unknown